Tapentadol Prolonged Release: A Review in Pain Management

Overview

Journal Drugs

Specialty Pharmacology

Date 2018 Nov 25

PMID 30471002

Citations 4

Authors

Emma D Deeks

Affiliations

Soon will be listed here.

Abstract

Tapentadol prolonged release (tapentadol PR) [Palexia SR in EU] is a long-acting tablet formulation of the strong central analgesic tapentadol, which acts as both a μ-opioid receptor (MOR) agonist and a noradrenaline reuptake inhibitor. Tapentadol PR is approved for chronic pain in various countries, with its EU indication (severe chronic pain manageable only with opioid analgesics) being the focus here. Well-designed trials and clinical practice data support tapentadol PR use in this setting. Short term, tapentadol PR was an effective and generally well tolerated analgesic for moderate to severe pain of varying aetiologies, including neuropathic pain. It provided analgesia at least as good as that of conventional strong opioids and appeared more favourable in terms of gastrointestinal tolerability, likely due to less potent MOR binding. Severe back pain with a neuropathic component responded well to moderate-dose tapentadol PR in some patients, while for others, an increase to the maximum recommended tapentadol PR dosage provided analgesia at least as good as that of moderate-dose tapentadol PR plus pregabalin and appeared to have some CNS tolerability benefits. Data also support the use of tapentadol PR in opioid rotation, including when conventional opioids are intolerable. Longer-term data in musculoskeletal pain conditions indicate continued benefit over up to 2 years' treatment with tapentadol PR with no evidence of tolerance. Thus, tapentadol PR is a useful option for the management of severe chronic pain.

Citing Articles

Novel Tapentadol Screen-Printed Carbon Sensor Integrated Copper Oxide Nanostructure.

Snari R, Al-Ahmed Z, Alharbi A, Sari A, Katouah H, Shah R ACS Omega. 2025; 10(3):2897-2907.

PMID: 39895769 PMC: 11780419. DOI: 10.1021/acsomega.4c09110.

Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation.

Coluzzi F, Rullo L, Scerpa M, Losapio L, Rocco M, Billeci D CNS Drugs. 2022; 36(6):617-632.

PMID: 35616826 PMC: 9166888. DOI: 10.1007/s40263-022-00924-2.

Comparing opioid types in the persistence of opioid use following surgical admission: a study protocol for a retrospective observational linkage study comparing tapentadol and oxycodone in Australia.

Lam T, Biggs N, Xia T, Evans J, Stevens J, da Gama M BMJ Open. 2022; 12(4):e060151.

PMID: 35418442 PMC: 9014068. DOI: 10.1136/bmjopen-2021-060151.

Oxycodone in the Opioid Epidemic: High 'Liking', 'Wanting', and Abuse Liability.

Kibaly C, Alderete J, Liu S, Nasef H, Law P, Evans C Cell Mol Neurobiol. 2020; 41(5):899-926.

PMID: 33245509 PMC: 8155122. DOI: 10.1007/s10571-020-01013-y.

Pharmacological rationale for tapentadol therapy: a review of new evidence.

Romualdi P, Grilli M, Canonico P, Collino M, Dickenson A J Pain Res. 2019; 12:1513-1520.

PMID: 31190962 PMC: 6526917. DOI: 10.2147/JPR.S190160.

References

Vadivelu N, Huang Y, Mirante B, Jacoby M, Braveman F, Hines R . Patient considerations in the use of tapentadol for moderate to severe pain. Drug Healthc Patient Saf. 2013; 5:151-9. PMC: 3704302. DOI: 10.2147/DHPS.S28829. View

Serrie A, Lange B, Steup A . Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study. Curr Med Res Opin. 2017; 33(8):1423-1432. DOI: 10.1080/03007995.2017.1335189. View

Etropolski M, Kuperwasser B, Flugel M, Haufel T, Lange B, Rauschkolb C . Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials. Adv Ther. 2014; 31(6):604-20. DOI: 10.1007/s12325-014-0128-6. View

Baron R, Jansen J, Binder A, Pombo-Suarez M, Kennes L, Muller M . Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial. Pain Pract. 2015; 16(5):600-19. DOI: 10.1111/papr.12361. View

Schwartz S, Etropolski M, Shapiro D, Rauschkolb C, Vinik A, Lange B . A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy. Clin Drug Investig. 2014; 35(2):95-108. PMC: 4300409. DOI: 10.1007/s40261-014-0249-3. View

Kress H, Koch E, Kosturski H, Steup A, Karcher K, Dogan C . Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain. Eur J Pain. 2016; 20(9):1513-8. PMC: 5071659. DOI: 10.1002/ejp.875. View

Baron R, Kern U, Muller M, Dubois C, Falke D, Steigerwald I . Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study. Pain Pract. 2014; 15(5):471-86. DOI: 10.1111/papr.12199. View

Raffaeli W, Arnaudo E . Pain as a disease: an overview. J Pain Res. 2017; 10:2003-2008. PMC: 5573040. DOI: 10.2147/JPR.S138864. View

Gohler K, Brett M, Smit J, Rengelshausen J, Terlinden R . Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations. Int J Clin Pharmacol Ther. 2013; 51(4):338-48. DOI: 10.5414/CP201722. View

10.

Ossipov M, Morimura K, Porreca F . Descending pain modulation and chronification of pain. Curr Opin Support Palliat Care. 2014; 8(2):143-51. PMC: 4301419. DOI: 10.1097/SPC.0000000000000055. View

11.

Smith H . Opioids and neuropathic pain. Pain Physician. 2012; 15(3 Suppl):ES93-110. View

12.

Biondi D, Xiang J, Etropolski M, Moskovitz B . Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis. Clin Drug Investig. 2014; 34(8):565-76. PMC: 4102827. DOI: 10.1007/s40261-014-0209-y. View

13.

Baron R, Likar R, Martin-Mola E, Blanco F, Kennes L, Muller M . Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study. Pain Pract. 2015; 16(5):580-99. DOI: 10.1111/papr.12308. View

14.

Baron R, Martin-Mola E, Muller M, Dubois C, Falke D, Steigerwald I . Effectiveness and Safety of Tapentadol Prolonged Release (PR) Versus a Combination of Tapentadol PR and Pregabalin for the Management of Severe, Chronic Low Back Pain With a Neuropathic Component: A Randomized, Double-blind, Phase 3b Study. Pain Pract. 2014; 15(5):455-70. DOI: 10.1111/papr.12200. View

15.

Biondi D, Xiang J, Etropolski M, Moskovitz B . Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain. J Opioid Manag. 2015; 11(5):393-403. DOI: 10.5055/jom.2015.0289. View

16.

Lange B, Sohns M, Tempero J, Elling C . Efficacy and safety of tapentadol prolonged release formulation in the treatment of elderly patients with moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo-, and active-controlled trials. Curr Med Res Opin. 2018; 34(12):2113-2123. DOI: 10.1080/03007995.2018.1520085. View

17.

Imanaka K, Tominaga Y, Etropolski M, Van Hove I, Ohsaka M, Wanibe M . Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Curr Med Res Opin. 2013; 29(10):1399-409. DOI: 10.1185/03007995.2013.831816. View

18.

Tzschentke T, Christoph T, Kogel B, Schiene K, Hennies H, Englberger W . (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007; 323(1):265-76. DOI: 10.1124/jpet.107.126052. View

19.

Leppert W . The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities. Contemp Oncol (Pozn). 2013; 16(2):125-31. PMC: 3687404. DOI: 10.5114/wo.2012.28792. View

20.

Lange B, von Zabern D, Elling C, Dubois C . Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies. Curr Med Res Opin. 2017; 33(8):1413-1422. DOI: 10.1080/03007995.2017.1335188. View